drugset / Trial / NCT00772590

Antiretroviral Therapy Intensification With Raltegravir or Addition of Hyper-immune Bovine Colostrum in HIV-1 Infected Patients With Suboptimal CD4+ T Cell Response

NCT00772590

Phase 4 Completed 75 enrolled Kirby Institute
RandomizedFactorialQuadruple-blindTreatment

Summary

A research study to measure the effect on CD4 counts of adding to current anti-retroviral regimen raltegravir with or without hyper-immune bovine colostrum.

Timeline

Start
2009-03
Primary completion
2010-03
Completion
2011-06

Drugs

EvaluationDrugModalityDoseRoute
Subject Raltegravir Other / unclassified 400 mg
Subject hyperimmune bovine colostrum Unknown 1800 mg